Next Article in Journal
Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions
Previous Article in Journal
Exploring the Utility of Circulating Endothelial Cell-Derived Extracellular Vesicles as Markers of Health and Damage of Vasal Endothelium in Systemic Sclerosis Patients Treated with Iloprost
 
 
Article
Peer-Review Record

Unravelling the Complexity of the +33 C>G [HBB:c.-18C>G] Variant in Beta Thalassemia

Biomedicines 2024, 12(2), 296; https://doi.org/10.3390/biomedicines12020296
by Coralea Stephanou 1,*,†, Miranda Petrou 1,†, Petros Kountouris 1, Christiana Makariou 2, Soteroula Christou 2, Michael Hadjigavriel 3, Marina Kleanthous 1,‡ and Thessalia Papasavva 1,‡
Reviewer 1: Anonymous
Reviewer 2:
Biomedicines 2024, 12(2), 296; https://doi.org/10.3390/biomedicines12020296
Submission received: 4 December 2023 / Revised: 12 January 2024 / Accepted: 18 January 2024 / Published: 27 January 2024
(This article belongs to the Special Issue Hemoglobin Molecule: A Structure-Function Interplay)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

It is a well writing paper regarding the genotype-phenotype findings of a new rare mutation of β-Thalassemia occuring more common in Cyprus. It is always valuable to publish data that provide new information which lead the genetic counseling.

One question: how do you explain the very high hemoglobin level of individual No 19?

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

In their manuscript „Unravelling the complexity of the +33 C>G [HBB:c.-18C>G] variant in beta thalassemia“ Coralea Stephanou et al conduct a complex study in which they describe a novel molecular variant that can have an aggravating effect in connection with pre-existing minimal thalassemia.

The manuscript describes very impressively the extensive work that was invested over several years and allows not only a genotypic but also a phenotypic classification.

Although the manuscript is very in-depth, there are some comments that the authors could adopt to improve it.

 

Major:

Unfortunately, Table 3 does not show a rigorous, complete analysis of all laboratory parameters, which were only comprehensively collected in around 18 of 26 clinical cases. Patient 3 is not assigned age.

 

Table 4, Patient 4. As Year of detection presumably dates to age of 23, year of onset at age 35 cannot be right. In addition, many explanatory laboratory parameters are missing from Table 4, especially in patient 6, who requires regular transfusions.

 

The pedigree shown in Figure 1 leaves a lot of room for imprecise interpretation. While the genetic situation of the father and index proband is described as a compound heterozygosity with no disease significance (IVS I-110 G>A variant), the mother also has a severe IVS I-110 G>A variant that is not otherwise described. This description needs further clarification.

 

Minor

Table 2 needs further layout improvements.

 

Figure 2 shows the essentials but remains in need of improvement in some areas in order to make the importance of the analysis more clear.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

Comments and Suggestions for Authors

I suggest accepting the manuscript in the present form.

Back to TopTop